Medivir – Interim Report, January – June 2016

HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News:

Medivir (STO:MVIRB)

Financial summary

Second quarter 2016

· Net turnover totalled SEK 81.3 million (245.8 m), of which SEK 24.2 million (165.6 m) comprised royalties for simeprevir.